Summary

The North America skin cancer dermatology market is expected to grow at a strong CAGR of around 6%. North America skin cancer dermatology market is anticipated to witness a surge in the availability of technologically advanced surgeries or procedures in hospitals and clinics such as dermatoscopy, skin biopsy, diagnostic imaging, and lymph node biopsy. This along with the rapidly growing skin cancer cases across the country is causing an increase in the number of patients and diagnoses. For instance, in July 2020, Genentech, a member of the Roche Group, stated that the U.S. Food and Drug Administration (FDA) sanctioned Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. Moreover, the most common cause of death caused due to melanoma due to climate change increasing sun exposure. Approx. 7,990 people are expected to die of melanoma as per the American Cancer Society, in 2023. Therefore, the demand for North America skin cancer dermatology is anticipated to grow in the forthcoming years.

Some of the major players operating in the market include Speclipse, Inc.; Agilent Technologies, Inc.; MetaOptima Technology Inc.; FotoFinder Systems, Inc; Canfield Scientific, Inc.; SkinIO, Inc.; Firefly Health, Inc.; DermLite; Eli Lilly and Company; Bristol-Myers Squibb Company Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst test type, skin biopsy segment held a significant market share in 2021”
Based on test type, the North America skin cancer dermatology market is segmented into skin biopsy and diagnostic imaging. The skin biopsy segment held a significant market share in 2021. This is mainly due to the higher adoption of the skin biopsy procedure due to the diagnosis of an extensive range of skin disorders for example basal cell carcinoma, squamous cell carcinoma, melanoma, and dermatitis. For instance, on May 18, 2022, LabCorp introduced the LAG-3 IHC assay, which is a new test for skin cancer treatment. The new assay measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue.

“Amongst age group, the 40-64 segment is expected to grow with a significant CAGR during the forecast period”
Based on age group, the market is segmented into 0-19, 20-39, 40-64, 65-84, and 85 and above. As per our analysis, the 40-64 segment is expected to grow with a significant CAGR during the forecast period. This is mainly attributed to the prolonged sun exposure with the rising rate of new melanomas of the skin cancer by age group that cause high demand of tanning kit among the population.

“Canada is expected to grow”
Canada expected to grow with a significant CAGR during the forecast period owing to the well-established dermatology medical specialty in Canada, with dermatologists playing a crucial role in the diagnosis, treatment, and management of skin diseases, including skin cancer. The Canadian Dermatology Association has played a crucial role in promoting the specialty and supporting the needs of dermatologists and their patients. Additionally, advances in technology and research have led to the development of new and more effective treatments for skin cancer, including immunotherapy and targeted therapy. As per the Canadian Skin Cancer Foundation in 2022, around 80,000 cases of skin cancer are diagnosed in Canada each year, and above 5,000 of these are melanoma, which is the deadliest form of skin cancer. Therefore, the above-mentioned factors fuel the growth of skin cancer dermatology in the country.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The North America skin cancer dermatology market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents